Information updates

Jorveza® is PBS listed for treatment of EoE

Jorveza® (budesonide) is an orally disintegrating tablet for the treatment of eosinophilic oesophagitis (EoE) in adults, that was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 May 2022.

Jorveza represents the first TGA approved and PBS subsidised medication for adults with this chronic and progressive, immune-mediated, oesophageal disease. The efficacy of Jorveza is supported by data from a phase III, randomised, double-blind, placebo-controlled, parallel group trial. The primary endpoint – clinicohistologic remission after six weeks – was met in 57.6% of patients receiving Jorveza (1mg twice daily; BID) versus 0% in the placebo group (p < 0.0001). At week 6 histologic remission was achieved in 93% of patients administered Jorveza, versus 0% in the placebo group (p < 0.0001). After 12 weeks, clinicohistologic remission was achieved in 84.7% of patients administered Jorveza. Jorveza was well-tolerated, and the most common adverse event reported was mild to moderate local candidiasis. No clinically relevant reduction in morning cortisol levels was documented.

Long-term maintenance treatment is recommended, as patients who discontinue treatment may experience a rapid relapse once remission is achieved. Jorveza is available in 1.0 mg tablets for inducing remission and 0.5/1.0 mg tablets for maintaining remission.

Copies of the product information for Jorveza® can be requested by calling Dr Falk Pharma Australia Pty Ltd on 1800 DRFALK (1800 373 255). 

Information about EoE is available on the ASCIA website www.allergy.org.au/patients/food-other-adverse-reactions

This news item was issued on 24 May 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.